The third drug has remained a black box — until now. Pfizer plans to block the activity ... analyst David Risinger said in a client note. Comirnaty, the Covid vaccine developed with BioNTech ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

Pfizer’s (PFE) stock has fallen ill since ... The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been ...

United States health authorities Monday gave full approval to the COVID-19 vaccine developed by Pfizer-BioNTech, which will now be marketed under the Comirnaty brand. Moderna's drug is expected to ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... with their COVID-19 vaccine Comirnaty could in future ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla ... the plummeting demand for its COVID vaccine Comirnaty and COVID antiviral Paxlovid, Bourla ...

Its adjusted earnings per share landed at $3.11, up 69% year over year. Pfizer's vaccine for COVID-19, Comirnaty, and its medicine for the disease, Paxlovid, combined for about $11.1 billion in ...